GlobalResearch and clinical trials
Inhaled molgramostim improved gas transfer in the lungs in autoimmune PAP in a phase 3 trial
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
The trial included 164 patients with autoimmune PAP. Patients inhaled molgramostim or placebo once a day. At 24 weeks, the gas transfer measurement rose by 9.8 points in the drug group. In the placebo group, the increase was 3.8 points. Quality-of-life scores also improved more in the drug group. Side effect rates were similar in both groups.
What does it mean for patients and families?
This inhaled treatment may become an alternative to lung washing (lavage) in the future. It is not news of an approval at this time. Treatment decisions are made with your doctor.
Source
Scientific paper: Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis. The New England Journal of Medicine, 2025. DOI: 10.1056/NEJMoa2410542 · PubMed 40834301
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Pulmonary alveolar proteinosis (PAP)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.